Evidence map›Paper›PMID 29212733›Full record

ArticleThe oncologist2018

Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α.

Smaranda Gazdaru, Lucien Perey, Anne Rosselet, Patrice Mathevet, Yves Chalandon, Nicolas Vulliemoz

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Smaranda GazdaruReproductive Medicine Unit, Department Woman Mother Child, Lausanne University Hospital, Lausanne, Switzerland.
Lucien PereyOncology Unit, Ensemble Hospitalier de la Côte, Morges, Switzerland.
Anne RosseletHematology Unit, Etablissements Hospitaliers du Nord Vaudois, Yverdon-les-Bains, Switzerland.
Patrice MathevetService of Gynaecology, Department Woman Mother Child, Lausanne University Hospital, Lausanne, Switzerland.
Yves ChalandonDepartment of Oncology, Hematology Division, Geneva University Hospitals, Geneva, Switzerland.
Nicolas VulliemozReproductive Medicine Unit, Department Woman Mother Child, Lausanne University Hospital, Lausanne, Switzerland nicolas.vulliemoz@chuv.ch.
University of Lausanne · CHHôpital de Morges · CHUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of tyrosine-kinase inhibitors (TKIs) has improved survival of patients with chronic myeloid leukemia (CML). Some patients may become resistant to TKIs and require hematopoietic stem cell transplant (HSCT) that is highly gonadotoxic. Fertility preservation with ovarian stimulation might be indicated but is challenging if patients need to remain on TKIs until HSCT because TKIs may compromise follicular development and response to ovarian stimulation. We report the case of a patient with CML resistant to TKI and planned for an HSCT, in which treatment by TKI was replaced by interferon-α before and during ovarian stimulation for fertility preservation. Successful ovarian stimulation was performed, allowing cryopreservation of nine zygotes. Hematopoietic stem cell transplantation was performed, and at present, 3 years later, the patient presents a sustained major molecular response.

Indexed as

AdultFemaleFertility PreservationHumansInterferon-alphaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveOvulation InductionProtein-Tyrosine KinasesPyrimidinesInterferon-alphanilotinibProtein-Tyrosine KinasesPyrimidines

Identifiers

PMID29212733
PMCPMC6067946
OpenAlexW2772239332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.